TITLE

STEROID USE IN ALCOHOLIC HEPATITIS: WHO, WHEN, AND WHY?

AUTHOR(S)
Heath, Bryan H.; Barkin, Jamie S.; Johnson, David A.; Cattau, Edward
PUB. DATE
April 1990
SOURCE
American Journal of Gastroenterology;Apr1990, Vol. 85 Issue 4, p473
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reviews the study "Methylprednisolone Therapy in Patients With Severe ALcoholic Hepatitis: Randomized Multicenter Trial," by R. L. Carrithers, F. Herlong, A. M. Diehl, E. W. Shaw, B. Combes, H. J. Fallon and W. C. Maddrey, published in the 1989 issue of the "Annals of Internal Medicine."
ACCESSION #
16018968

 

Related Articles

  • Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis. Martí-Bonmatí, Luis; Fog, Amura F.; de Beeck, Bart Op; Kane, Pauline; Fagertun, Hans; Martí-Bonmatí, Luis // European Radiology;Jul2003, Vol. 13 Issue 7, p1685 

    Mangafodipir trisodium (Mn-DPDP, Teslascan) is a well-tolerated liver contrast agent. Although the enhancement characteristics of the cirrhotic liver after Mangafodipir trisodium administration have been studied, at present there is no published data on the impact that cirrhosis might have on...

  • Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Snow, Kristin K.; Bell, Margaret C.; Stoddard, Anne M.; Curto, Teresa M.; Wright, Elizabeth C.; Dienstag, Jules L. // Trials;2014, Vol. 15 Issue 1, p1 

    Background The timely publication of findings in peer-reviewed journals is a primary goal of clinical research. In clinical trials, the processes leading to publication can be complex from choice and prioritization of analytic topics through to journal submission and revisions. As little...

  • The Maze of Treatments for Hepatitis B. Lok, Anna Suk-Fong // New England Journal of Medicine;6/30/2005, Vol. 352 Issue 26, p2743 

    Comments on the treatment of Hepatitis B virus (HBV). Incidence of HBV infections and mortality associated with the disease each year; Goal of treating HBV infection prior to significant liver damage; Description of the five approved therapies for HBV infection; Comparison of the efficacy of...

  • The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment.  // ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p4 

    This article reports on a study conducted to examine the efficacy of adefovir dipivoxil in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. 120 patients with HBeAg-negative chronic hepatitis B and compensated liver disease, who had received treatment with adefovir...

  • Gilead's drug promising in hepatitis B.  // PharmaWatch: Biotechnology;Dec2007, Vol. 6 Issue 12, p7 

    The article reports on the announcement of Gilead Sciences Inc. concerning the positive findings from two of its Phase III pivotal clinical trials, which evaluate the safety and efficacy of once-daily Viread for adult patients with chronic hepatitis B virus infection in the U.S. According to the...

  • Remission in Autoimmune Hepatitis: What Is It, and Can It Ever Be Achieved? Al-Chalabi, Thawab; Heneghan, Michael A. // American Journal of Gastroenterology;May2007, Vol. 102 Issue 5, p1013 

    The goals of therapy in autoimmune hepatitis (AIH) are to dampen inflammation within the liver, with the aim of inducing remission, improving symptoms, and prolonging survival. Ideally, treatment could be stopped once remission has been achieved. However, cessation of therapy may be complicated...

  • A Balancing View: A Decision to be Shared with Patients. Shiffman, Mitchell L. // American Journal of Gastroenterology;Jun2004, Vol. 99 Issue 6, p975 

    Discusses issues on whether to treat or not to treat patients with chronic hepatitis C virus and normal serum alanine aminotransferase. Progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase levels; Significance of serum alanine aminotransferase...

  • PRO: Most Patients Should be Treated. Koff, Jonathan M.; Younossi, Zobair // American Journal of Gastroenterology;Jun2004, Vol. 99 Issue 6, p972 

    Discusses the management for hepatitis C with normal liver enzymes. Reasons for treating chronic hepatitis C-infected patients regardless of their alanine aminotransferase levels; Examination of liver histology in chronic hepatitis C-infected patients who have normal alanine aminotransferase...

  • VITAGEN ANNOUNCES ENROLLMENT FOR PHASE II TRIAL OF ELAD(r) BIOARTIFICIAL LIVER SUPPORT THERAPY. Stern, Aron // Internet Journal of Infectious Diseases;2002, Vol. 2 Issue 2, p68 

    VitaGen Inc. announced today that it is currently enrolling patients with fulminant hepatic failure (FHF) in a multicenter Phase II clinical trial.These patients represent a similar patient population to those studied in the successfully completed Phase I/II trial, but include patients at...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics